



Idera Pharmaceuticals to Participate in a Panel Discussion at the Piper Jaffray GenomeRx Symposium

June 17, 2014 12:00 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 17, 2014-- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage biopharmaceutical company developing nucleotide therapeutics for patients with cancer and orphan diseases, today announced that Sudhir Agrawal, D. Phil., Chief Executive Officer, will participate in a panel discussion entitled "*RNA/DNA: Getting It Where You Need It*" at the Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014. The panel is scheduled to begin at 3:30 p.m. EDT and will take place in New York City.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. Idera's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.
Sarah Carmody, 617-679-5552
scarmody@iderapharma.com